MaaT013

MaaT Pharma to host a webinar on Dec 17, 2024, discussing MaaT013's efficacy in aGvHD, showing 51% GI-ORR at Day 28 and 47% OS at 12 months. Phase 3 ARES trial results expected Jan 2025. MaaT013 aims to modulate the immune system via microbiome therapy, addressing aGvHD's unmet medical needs.

MaaT Pharma to host a KOL webinar on Dec 17, 2024, discussing aGvHD data. MaaT013 showed 51% GI-ORR and 49% ORR at Day 28, with 47% OS at 12 months and 42% at 24 months. Median OS for responders was 444 days vs. 42 days for non-responders. ARES Phase 3 trial results expected Jan 2025.

MaaT Pharma announces a webinar on Dec 17, 2024, to discuss MaaT013's efficacy in treating acute Graft-versus-Host Disease (aGvHD), showing 51% GI-ORR at Day 28 and 47% OS at 12 months. Phase 3 ARES trial results expected Jan 2025.

MaaT Pharma treated its first U.S. patient with MaaT013 for acute graft-versus-host disease under a compassionate access program at City of Hope Hospital, via an FDA-approved single-patient expanded access program.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

MaaT013 shows high efficacy and safety in treating refractory GI-aGvHD, with significant survival benefits observed in long-term follow-up. A Phase 3 trial (ARES) completed in 2024, with topline results expected in 2025, further supports MaaT013's potential as a transformative therapy for GI-aGvHD patients.

MaaT Pharma completed recruitment for its phase 3 trial of MaaT013, evaluating its efficacy and safety in treating steroid and ruxolitinib-refractory acute graft-versus-host disease (aGvHD). The study, ARES, enrolled 66 evaluable patients, with topline results expected in January 2025. MaaT013 aims to restore gut microbiome balance for immune modulation, potentially becoming the first microbiome-driven therapy in oncology.

MaaT Pharma completes Phase 3 ARES trial enrollment, with topline results expected in Jan 2025. The DSMB reviewed the trial positively, noting high efficacy and low toxicity. Registration submission is planned for 2025 in Europe.

MaaT Pharma announced full recruitment for its Phase 3 trial of MaaT013, evaluating its efficacy and safety in treating steroid and ruxolitinib refractory acute Graft-versus-Host Disease (aGvHD). Topline results, including the primary endpoint, are expected in January 2025. MaaT013 aims to optimize gut microbiota balance and reduce adverse events, potentially becoming the first microbiome-driven therapy in oncology.